Teton Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Teton Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,000	Closed	-$321K	–	372
2021 Q4	$321K	Hold	11,000	–	–	0.05%	330
2021 Q3	$293K	Hold	11,000	–	–	0.04%	342
2021 Q2	$339K	Hold	11,000	–	–	0.05%	326
2021 Q1	$288K	Sell	11,000 -7,300	-40%	-$204K	0.04%	327
2020 Q4	$460K	Hold	18,300	–	–	0.06%	302
2020 Q3	$381K	Hold	18,300	–	–	0.07%	283
2020 Q2	$435K	Sell	18,300 -2,700	-13%	-$59.7K	0.07%	289
2020 Q1	$378K	Hold	21,000	–	–	0.06%	302
2019 Q4	$498K	Buy	21,000 +12,200	+139%	+$296K	0.05%	330
2019 Q3	$242K	Buy	+8,800	New	+$261K	0.02%	409

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Teton Advisors's SUPN Position: Q1 2022 in Review

Teton Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 11,000 shares — an estimated $321K sold.

Teton Advisors first reported a position in SUPN in Q3 2019 and held it in 10 quarters. The position peaked at $498K in Q4 2019. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

Teton Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Teton Advisors sold 11,000 Supernus Pharmaceuticals shares in Q1 2022, an estimated $321K.
Teton Advisors first reported a position in Supernus Pharmaceuticals in Q3 2019 and held it in 10 quarters.
Teton Advisors's Supernus Pharmaceuticals position peaked at $498K in Q4 2019.
230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Teton Advisors's 13F filing for Q1 2022, filed 13 May 2022.